Edition:
United Kingdom

Novavax Inc (NVAX.OQ)

NVAX.OQ on NASDAQ Stock Exchange Global Select Market

1.64USD
25 Apr 2018
Change (% chg)

$0.06 (+3.80%)
Prev Close
$1.58
Open
$1.59
Day's High
$1.67
Day's Low
$1.53
Volume
1,628,769
Avg. Vol
1,907,073
52-wk High
$2.75
52-wk Low
$0.73

Chart for

About

Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates... (more)

Overall

Beta: 1.98
Market Cap(Mil.): $338.31
Shares Outstanding(Mil.): 294.18
Dividend: --
Yield (%): --

Financials

  NVAX.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.77 -- --
ROI: -57.83 1.58 14.38
ROE: -829.23 2.41 16.07

BRIEF-Novavax Prices Public Offering 30.3 Mln Common Shares At $1.65 Per Share

* SAYS PUBLIC OFFERING OF 30.3 MILLION COMMON SHARES PRICED AT $1.65PER SHARE

12 Apr 2018

BRIEF-Novavax Inc Q4 Loss Per Share $0.16

* NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS

14 Mar 2018

BRIEF-Novavax Inc Promotes John Trizzino To CFO Role

* NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER

14 Mar 2018

BRIEF-Novavax Sees Phase 2 Trial Of Nanoflu Vaccine To Begin In Q3 2018

* SAYS PHASE 2 TRIAL OF NANOFLU VACCINE EXPECTED TO BEGIN IN Q3 OF 2018

28 Feb 2018

BRIEF-Novavax Inc Files For Mixed Shelf Of Up To $200 Mln

* NOVAVAX INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2zNiPwp) Further company coverage:

29 Dec 2017

BRIEF-Novavax Files Prospectus Supplement Related To Issuance, Sale Of Up To $75 Mln Of Common Stock

* NOVAVAX INC FILES PROSPECTUS SUPPLEMENT RELATES TO THE ISSUANCE AND SALE OF UP TO $75 MILLION OF COMMON STOCK -SEC FILING‍​ Source text: (http://bit.ly/2Edci1c) Further company coverage:

29 Dec 2017

BRIEF-Novavax Continues Phase 3 Trial Of RSV F Vaccine For Infants Via Maternal Immunization

* NOVAVAX CONTINUES PHASE 3 TRIAL OF THE RSV F VACCINE FOR INFANTS VIA MATERNAL IMMUNIZATION AND PROVIDES UPDATE ON PHASE 1/2 TRIAL OF THE NANOFLU™ VACCINE Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-Novavax Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

07 Nov 2017

BRIEF-Novavax reports Q3 loss per share $0.15

* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S

07 Nov 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF75.24 -0.52
Merck & Co., Inc. (MRK.N) $59.63 -0.46
Sanofi SA (SASY.PA) €65.87 --
GlaxoSmithKline plc (GSK.L) 1,412.20 -50.00
AstraZeneca plc (AZN.L) 4,991.00 +1.50

Earnings vs. Estimates